ICCC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ImmuCell Corp (ICCC) is not a strong buy for a beginner, long-term investor at this time. While the technical indicators show some bullish trends, the company's recent financial performance is weak, with significant declines in revenue, net income, and EPS. Additionally, there are no strong positive catalysts or trading signals to justify immediate investment. It is better to monitor the stock for improved financial performance or stronger market signals before considering a buy.
The MACD is positive and expanding, indicating a bullish momentum. The RSI is neutral at 62.015, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above key support levels, with resistance at 6.715 and 6.899. Overall, the technicals suggest a mild bullish trend.
The company has a strong gross margin improvement (up 62.95% YoY) and is committed to transparency, as evidenced by its upcoming financial report and annual filing.
No significant hedge fund or insider trading activity. No recent congress trading data. Weak stock trend projections for the next day, week, and month.
In Q3 2025, revenue decreased to $5,506,122 (-8.41% YoY), net income dropped to -$139,748 (-80.08% YoY), and EPS fell to -0.02 (-77.78% YoY). Gross margin improved to 42.92% (+62.95% YoY), but overall financial performance remains weak.
No analyst rating or price target data available.
